Clincosm LogoSign in Get a demo

COVID-19 Associated With Psoriasis

Sponsor
Gang Wang, MD (Other)
Overall Status
Recruiting
CT.gov ID
NCT05961605
Collaborator
(none)
2,500
Enrollment
12
Locations
4.5
Anticipated Duration (Months)
208.3
Patients Per Site
46.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A retrospective analysis based on database was conducted to evaluate the correlation between covid-19 infection and the condition and treatment of psoriasis patients.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Based on the patients registered in the psoriasis patient database of each center, the patients were followed up by telephone, and the severity of covid-19 infection, the change of psoriasis condition and the adjustment of treatment methods of psoriasis patients were collected for retrospective analysis.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    2500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Retrospective Clinical Study of COVID-19 Associated With the Condition and Treatment of Patients With Chinese Psoriasis
    Actual Study Start Date :
    Mar 15, 2023
    Actual Primary Completion Date :
    May 30, 2023
    Anticipated Study Completion Date :
    Jul 30, 2023

    Outcome Measures

    Primary Outcome Measures

    1. The recurrence/exacerbation of psoriasis following SARS-CoV-2 infection [March 15,2023 to May 30,2023]

      The impact of SARS-CoV-2 infection on psoriasis in patients receiving different baseline therapies of psoriasis.

    Secondary Outcome Measures

    1. Univariate and multivariate analyses identify risk factors with psoriasis exacerbation/recurrence after SARS-CoV-2 infection [March 15,2023 to May 30,2023]

      Univariate and multivariate analyses identify risk factors with psoriasis exacerbation/recurrence after SARS-CoV-2 infection

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion criteria ----

    1. No age limit, both male and female are accepted;

    2. Psoriasis patients registered in the database;

    3. Patients or their families can cooperate to complete the follow-up information survey (questionnaire, telephone, etc.) independently, and ensure the authenticity of the data provided.

    Exclusion criteria ----

    Patients are thought having conditions which are not appropriated for attending this clinical trial.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing China 400016
    2 The First Hospital of Lanzhou University Lanzhou Gansu China 730000
    3 Dermatology Hospital of Southern Medical University Guangzhou Guangdong China 510091
    4 The Second Hospital of Jilin University Changchun Jilin China 130041
    5 Dalian Dermatosis Hospital Dalian Liaoning China 116021
    6 Xining First People's Hospital Xining Qinghai China 810000
    7 Xijing Hospital, The Fourth Military Medical University Xi'an Shaanxi China 710032
    8 Shanghai Skin Disease Hospital, Tongji University School of Medicine Shanghai Shanghai China 200443
    9 The University of Hong Kong-Shenzhen Hospital Shenzhen Shenzhen China 518053
    10 West China Hospital, Sichuan University Chengdu Sichuan China 610041
    11 Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital Tianjin Tianjin China 300021
    12 People's Hospital of Xinjiang Uygur Autonomous Region，Xinjiang Key Laboratory of Dermatology Research Ürümqi Xinjiang China 830001

    Sponsors and Collaborators

    • Gang Wang, MD

    Investigators

    • Principal Investigator: GANG WANG, M.D., Xijing Hospital, The Fourth Military Medical University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Gang Wang, MD, Chief Director of Department of Dermatology, Xijing Hospital
    ClinicalTrials.gov Identifier:
    NCT05961605
    Other Study ID Numbers:
    • XJPF202303-PSO&COVID-19
    First Posted:
    Jul 27, 2023
    Last Update Posted:
    Aug 1, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Gang Wang, MD, Chief Director of Department of Dermatology, Xijing Hospital
    psoriasis
    covid-19
    Additional relevant MeSH terms:
    COVID-19
    Psoriasis

    Study Results

    No Results Posted as of Aug 1, 2023